Deep Genomics Pitch Deck: Slide-by-Slide Breakdown

Deep Genomics: A Data-First Approach to Biotechnology

The Deep Genomics Series C pitch deck, presented in May 2021, represents a pivotal moment for the company. At this stage, the narrative shifted from 'we have a cool AI tool' to 'we are a clinical-stage powerhouse with a multi-billion dollar pipeline.' The deck is structured to prove that their digital framework for RNA biology is not just theoretical but is actively producing first-in-class therapies at a rate traditional biotech firms cannot match.

Slides 1-3: The Vision and the Equation

Slide 1 introduces the leadership team, including Brendan Frey (CEO), Amanda Kay (CBO), Ferdinand Massari (CMO), and Matt Cahill (Head of Finance). The imagery of a modern lab sets the professional tone expected for a Series C round.

Slide 2 establishes the 'Why.' It posits that the digital nature of RNA therapies has sparked a revolution, but winning requires mastering the 'enormous complexity of RNA biology.' This sets up the problem that only a high-compute solution can solve.

Slide 3 provides the 'Deep Genomics Equation': Digital RNA Biology Platform x 10^17 Bytes of Data x Artificial Intelligence = Deep Genomics. The claim here is bold: 'Programming the best RNA therapies for almost any gene in any genetic condition.' By using the word 'programming' instead of 'discovering,' the company aligns itself with the high-margin, scalable world of software rather than the high-failure world of traditional biology.

Slides 4-6: The Framework and Momentum

Slide 4 illustrates the 'digital framework for untangling complexity.' It shows the biological flow from DNA to Protein, highlighting where their Steric Blocking Oligonucleotide (SBO) intervenes at the pre-mRNA level. This slide is crucial for technical due diligence, showing exactly where their 'Digital RNA Therapy' fits into the central dogma of molecular biology.

Slide 5 is the 'Traction' slide. It compares 2019 to 2021. In two years, the company grew from 2 programs to 10 programs, and from 1 RNA mechanism to 7. Most importantly, it notes a partnership with BioMarin and an increase in estimated peak sales from $400M to over $5B. It also highlights their geographic footprint: AI and Preclinical research in Toronto, and Clinical/Business development in Boston.

Slide 6 is a 'Power Team' slide. Beyond the executive team, it lists heavy-hitting advisors like Steve Jurvetson (Tesla/SpaceX board), Peter Barton Hutt (FDA/Moderna), and Yann LeCun (Facebook AI). The inclusion of a grid of photos of the entire staff at the bottom emphasizes the human capital behind the 10^17 bytes of data.

Slides 7-9: The AI Workbench Advantage

Slide 7 directly attacks the traditional drug discovery model. Traditional methods are described as 'bespoke' and 'trial & error,' where risk is managed sequentially. Deep Genomics claims to 'derisk all up front' through prediction at scale. This is the core value proposition for a Series C investor: efficiency and higher probability of success.

Slide 8 defines their 'Predictors.' The company has 40 of them, used to identify novel targets, design therapies, and predict safety/toxicity. It specifically mentions SBO predictors for protein restoration, expression increase, and knockdown.

Slide 9 visualizes the 'AI Workbench' as a flywheel. It claims 1 billion predictions covering every gene and 300,000 variants. The output is 600,000 efficacy and safety datapoints across 20,000 RNA therapies. This slide quantifies the 'Data' part of the equation from Slide 3, proving the scale of their digital operations.

Slides 10-12: Market Application and Economics

Slide 10 shows the company's trajectory from 'Mendelian Recessive' diseases (lower complexity/prevalence) to 'Complex Many Effects' diseases (high complexity/prevalence). This suggests that while they are starting with rare genetic disorders, their AI is built to eventually tackle massive, complex disease markets.

Slide 11 is the pipeline chart. It lists specific indications in CNS (Frontotemporal Dementia, Parkinson's) and Metabolic (Wilson Disease, Gout) areas. The 'Est. WW Peak Sales' column is the 'hook' for investors, showing multiple billion-dollar opportunities. It also shows four programs partnered with BioMarin, providing external validation of their tech.

Slide 12 summarizes why the AI Workbench drives 'outsized returns.' It claims to increase the probability of preclinical success from 10% to 50%. In the world of drug development, a 5x increase in success probability is a transformative economic claim.

Slides 13-16: The Ask and Future Outlook

Slide 13 provides a bar chart of the portfolio growth, projecting a steady increase in discovery, preclinical, and clinical programs through 2024. It shows the company reaching a 'tipping point' for clinical expansion.

Slide 14 is the 'Ask' and 'Use of Funds' slide. The $180M investment is intended to: expand AI predictors, screen 100 genes, secure 80 targets with patented leads, expand partnerships, and move 4 programs into the clinic (representing $4.5B in peak sales). This is a very specific and measurable set of milestones for a Series C round.

Slide 15 is a simple 'Thank You' with lab imagery, and Slide 16 is a standard promotional slide for the platform where the deck was hosted.

What Works in This Deck

The Platform-to-Pipeline Narrative: The deck successfully argues that Deep Genomics is not just a software company, but a drug development company that uses software to win. By showing a pipeline with $5B+ in peak sales (Slide 5), they move the conversation from 'R&D costs' to 'Asset value.'

Quantified Advantage: Claiming a jump from 10% to 50% success probability (Slide 12) is a bold, memorable metric. Even if investors discount it, it sets a high bar for the company's perceived efficiency.

Validation: The BioMarin partnership (Slide 11) and the high-profile advisors (Slide 6) provide the necessary 'social proof' to back up the complex technical claims.

What is Missing

Unit Economics: While the deck mentions peak sales, it does not detail the cost to bring a single program to the clinical stage compared to industry averages. A Series C investor would likely want to see how much cheaper/faster their 'AI Workbench' actually makes the discovery phase in dollar terms.

Competitive Landscape: There is no mention of other AI-driven drug discovery firms (e.g., Recusion, Exscientia, Insitro). In a crowded 'AI for Bio' space, explaining why their focus on RNA and SBOs is superior to other modalities is a missed opportunity.

Detailed Clinical Data: For a company claiming to be at a 'tipping point' for clinical expansion, the deck is light on actual data from their preclinical trials. It relies heavily on 'predictions' rather than 'results' in this specific presentation format.

What a Founder Should Copy

The 'Flywheel' Visualization: Slide 9 is an excellent way to show how data, AI, and physical lab work interact to create a competitive moat. Founders should use similar loops to show how their business gets stronger with every iteration.

Specific Use of Funds: Slide 14 is a perfect example of how to present a large round. Instead of just saying 'hiring and R&D,' they give specific numbers: 100 genes, 80 targets, 4 clinical programs. This creates accountability and a clear roadmap for the next 18-24 months.

The 'Equation' Slide: Slide 3 simplifies a very complex business into a single line. If you can't summarize your company as a simple 'A + B = C' equation, you might not have a clear enough grasp of your core value driver.